Novanta (US:NOVT)2026-02-23 21:57Revenue and Market Segmentation - Total revenue for 2025 was $980.6 million, an increase of $31.4 million, or 3.3%, compared to 2024, driven by acquisitions and growth in the Automation Enabling Technologies segment [219]. - The medical market accounted for approximately 53% of total revenue, while the advanced industrial market accounted for approximately 47% [209][210]. - The Automation Enabling Technologies segment revenue increased by $10.2 million, or 2.1%, primarily due to a $30.3 million increase in robotics and automation products [225]. - Medical Solutions segment revenue increased by $21.1 million, or 4.6%, driven by a $33.7 million increase in advanced surgery products [226]. Income and Earnings - Operating income for 2025 was $94.0 million, a decrease of $16.6 million, or 15.0%, compared to 2024, primarily due to increased SG&A expenses and restructuring costs [220]. - Basic and diluted earnings per share for 2025 were both $1.47, a decrease of $0.31 and $0.30, respectively, from 2024 [221]. - Net income for 2025 was $53.8 million, down from $64.1 million in 2024 [252]. Expenses - Total operating expenses for 2025 were $341.3 million, a 9.7% increase from $311.0 million in 2024 [231]. - Research and development expenses were $95.5 million, or 9.7% of revenue, in 2025, unchanged from 2024 [233]. - Selling, general and administrative expenses rose to $195.7 million, or 20.0% of revenue, from $175.9 million, or 18.5% of revenue in 2024 [235]. - Medical Solutions segment operating income decreased to $51.2 million, or 10.7% of revenue, from $57.5 million, or 12.5% in 2024 [242]. Cash and Financing - As of December 31, 2025, the company had $380.9 million in cash and cash equivalents, with $67.6 million held by subsidiaries outside North America [256]. - The company issued 12,650,000 tangible equity units at a public offering price of $50.00 per unit, raising $632.5 million in total [211]. - Cash and cash equivalents totaled $380.9 million as of December 31, 2025, a significant increase from $114.0 million as of December 31, 2024, primarily due to proceeds from the issuance of tangible equity units [269]. - The company had $276.3 million in net cash provided by financing activities in 2025, driven by proceeds from tangible equity units and borrowings under credit facilities [274]. Debt and Credit Facilities - The Fourth Amended and Restated Credit Agreement provides for an aggregate credit facility of approximately $1.0 billion, maturing in June 2030 [215]. - As of December 31, 2025, the company had $74.0 million (€63.1 million) outstanding under Euro Term Loans and $75.0 million outstanding under U.S. Term Loans, with no outstanding revolver borrowings [264][265]. - Future interest payments under the Senior Credit Facilities are estimated to be approximately $33.6 million through maturity, with $8.1 million payable within the next twelve months [280]. - As of December 31, 2025, the company had $110.6 million outstanding under Amortizing Notes, which bear interest at 6.30% per annum [268][282]. - The maximum consolidated leverage ratio permitted under the Fourth Amended and Restated Credit Agreement was increased to 3.75:1.00, with a step-up to 4.25:1.00 for certain acquisitions [262]. Tax and Legal Matters - A valuation allowance of $4.6 million was established in 2025 for net operating losses and other timing items in certain tax jurisdictions [317]. - As of December 31, 2025, the total amount of gross unrecognized tax benefits was $4.4 million, with $3.7 million potentially favorably affecting the effective tax rate if recognized [318]. - The estimated unrecognized income and foreign withholding tax liabilities on undistributed earnings from foreign subsidiaries is approximately $5.4 million [319]. - Legal proceedings and claims are reviewed quarterly, with liabilities accrued for probable losses that can be reasonably estimated [320]. Inventory and Impairment - The company regularly reviews inventory and may increase provisions for excess and obsolete inventory if sales do not meet forecasts [295]. - Impairment analyses of goodwill and indefinite-lived intangible assets are conducted annually, with no impairment noted as of the beginning of the second quarter of 2025 [312]. - The company assesses indefinite-lived intangible assets for impairment annually, with impairment recognized if fair value is less than carrying value [308]. Foreign Currency and Interest Rate Risk - The company had foreign currency contracts with notional amounts totaling $147.7 million and a net fair value of less than $0.1 million as of December 31, 2025 [325]. - A hypothetical 10% strengthening of the U.S. dollar against other currencies would result in an approximately $10.2 million increase in the net fair value of the company's foreign currency contracts as of December 31, 2025 [325]. - Conversely, a hypothetical 10% weakening of the U.S. dollar against other currencies would result in an approximately $10.2 million decrease in the net fair value of the company's foreign currency contracts as of December 31, 2025 [326]. - The company had $149.0 million of outstanding variable rate debt as of December 31, 2025 [327]. - A 100 basis point increase in interest rates at December 31, 2025 would increase the company's annual pre-tax interest expense by approximately $1.5 million [327]. Other Financial Information - The company expects to use approximately $20 million to $25 million in 2026 for capital expenditures related to investments in new property, plant, and equipment [273]. - Share-based compensation expenses are recognized based on fair value at grant date, with various performance-based awards impacting expense recognition [296]. - Revenue is recognized at a point in time upon shipment, with professional services accounting for less than 3% of consolidated revenue [289]. - The company provides warranties for products, typically ranging from 12 to 36 months, with warranty costs estimated based on historical experience [293].